Study guide

5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas

Key Takeaways Explain This Topic AI

Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) is the most common leukemia in adults in Western countries, characterized by absolute persistent clonal lymphocytosis (≥5.0 × 10^9/L) of small mature lymphocytes with 'soccer-ball' clumped chromatin and abundant fragile smudge cells (basket cells).

Smudge cells in CLL are mechanical artifacts of slide preparation; adding 1 drop of 22% bovine serum albumin to 4–5 drops of EDTA blood stabilizes fragile cell membranes, allowing an accurate manual differential count without altering cellular morphology.

The diagnostic immunophenotype of CLL is the co-expression of pan-B-cell antigens (CD19+, CD20+ dim, CD23+) with the T-cell antigen CD5+, along with CD200+ bright, CD43+, and dim monoclonal surface immunoglobulin light chain restriction (kappa or lambda dim); it is CD10- and Cyclin D1-.

High-risk CLL prognostic markers include unmutated IGHV status, del(17p) / TP53 mutation (conferring chemoimmunotherapy resistance), del(11q) / ATM mutation, and high expression of CD38 or ZAP-70; del(13q) as a sole abnormality and mutated IGHV indicate a favorable prognosis.

Hairy Cell Leukemia (HCL) is an indolent B-cell neoplasm in middle-aged males presenting with massive splenomegaly, pancytopenia, severe monocytopenia, and dry tap; malignant cells display circumferential hair-like projections, Tartrate-Resistant Acid Phosphatase (TRAP) positivity, the BRAF V600E mutation, and CD11c+, CD25+, CD103+, CD123+, Annexin A1+ expression.

Last updated: August 2026

Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas

Mature B-cell neoplasms encompass a spectrum of clonal lymphoproliferative disorders originating from post-thymic, mature B-lymphocytes at various stages of differentiation (pre-germinal center, germinal center, or post-germinal center/memory cells). These disorders range from indolent, slowly progressive leukemias and lymphomas to aggressive, rapidly fatal malignancies.

1. Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in adults in Western countries, with a median age at diagnosis of 70 to 72 years and a 2:1 male-to-female predominance. CLL and Small Lymphocytic Lymphoma (SLL) are identical biologic and immunophenotypic entities; the designation CLL is applied when there is persistent absolute peripheral blood monoclonal lymphocytosis ≥ 5.0 × 10 9 / L \ge 5.0 \times 10^9/\text{L} ≥ 5.0 × 1 0 9 / L ( 5 , 000 / μ L 5,000/\mu\text{L} 5 , 000/ μ L ) , whereas SLL is diagnosed when the disease is restricted to lymph nodes and spleen with < 5.0 × 10 9 / L <5.0 \times 10^9/\text{L} < 5.0 × 1 0 9 / L circulating clonal B-cells. CLL / SLL DIAGNOSTIC BIFURCATION

  • │
  • ┌───────────────────────────┴───────────────────────────┐
  • ▼ ▼
  • [ CHRONIC LYMPHOCYTIC LEUKEMIA ] [ SMALL LYMPHOCYTIC LYMPHOMA ]
  • Peripheral Blood Monoclonal B-Cells • Nodal, Splenic, or Tissue Disease
  • ≥ 5.0 × 10^9/L • Peripheral Clonal B-Cells < 5.0 × 10^9/L
  • Bone Marrow Infiltration ≥30% • Identical Morphology & Immunophenotype
  • Peripheral Blood Smear Morphology & The Smudge Cell Phenomenon

Monotonous Lymphocytosis : The peripheral blood is dominated by small, mature-appearing lymphocytes with high nuclear-to-cytoplasmic (N:C) ratios, narrow rims of pale-blue agranular cytoplasm, and round nuclei with densely clumped, block-like chromatin classically described as having a "soccer-ball" or "cracked-mud" appearance . Nucleoli are absent or small and inconspicuous.

Prolymphocytes : In typical CLL, prolymphocytes (larger cells with moderate cytoplasm and a prominent central vesicular nucleolus) comprise < 15 % <15\% < 15% of circulating lymphoid cells. When prolymphocytes comprise 15 – 55 % 15\text{--}55\% 15 – 55% , the disease is classified as CLL with increased prolymphocytes (CLL/PL) ; if > 55 % >55\% > 55% , it is classified as B-cell Prolymphocytic Leukemia (B-PLL) , an aggressive disorder.

Smudge Cells (Gumprecht Shadows / Basket Cells) : Smudge cells are damaged, ruptured leukemic lymphocytes that appear as pale, pink-purple, structureless, smudged nuclear remnants on Romanowsky-stained smears. Because CLL lymphocytes have a defective vimentin-based cytoskeleton, they are exceptionally fragile and rupture under the mechanical shearing forces of spreading a blood drop on a glass slide. THE ALBUMIN RECONSTITUTION TECHNIQUE

  • Problem: Excessive Smudge Cells Rupture on Routine Peripheral Smear
  • └──► Inaccurate Automated & Manual WBC Differential Counts
  • Solution: [ 1 Drop of 22% Bovine Serum Albumin ] + [ 4 - 5 Drops of EDTA Whole Blood ]
  • │
  • ▼
  • Mix Thoroughly & Prepare Manual Wedge Smear
  • │
  • ▼
  • Albumin Increases Oncotic Support & Stabilizes
  • Fragile Leukemic Cytoskeletons
  • │
  • ▼
  • Result: Intact Lymphocyte Morphology Restored for
  • Accurate 100-Cell Manual Differential
  • Laboratory Technique & Board Rule: Albumin Smear Preparation

When smudge cells are numerous on a routine peripheral blood film, they can prevent an accurate manual differential count.

Protocol : Add 1 drop of 22% bovine serum albumin to 4 to 5 drops of EDTA-anticoagulated whole blood , mix gently, and prepare a new wedge smear.

Effect : Albumin provides oncotic support and structural stabilization to the fragile cytoplasmic membranes, preventing cellular lysis during smearing while leaving cellular morphologic characteristics intact.

Reporting Rule : The albumin-treated slide is used strictly for performing the manual differential count . The absolute WBC count, hemoglobin, hematocrit, and red cell/platelet morphologies must always be evaluated and reported from the original non-albumin EDTA blood sample.

Multiparameter Flow Cytometric Immunophenotype

Flow cytometry on peripheral blood or bone marrow is the definitive diagnostic modality for CLL. Malignant CLL cells display a distinctive immunophenotypic profile:

Pan-B-Cell Markers : CD19+ , CD20+ (characteristically DIM) , CD22+ (dim) , and CD79a+ .

Aberrant T-Cell Antigen Co-Expression : CD5+ (co-expressed aberrantly on the clonal B-cells).

Key Positive Markers : CD23+ (bright) , CD200+ (uniformly bright) , and CD43+ .

Clonal Light Chain Restriction : Surface immunoglobulin ( sIg ) is characteristically DIM , showing monoclonal restriction to either κ \kappa κ (kappa) dim or λ \lambda λ (lambda) dim .

Key Negative Markers : CD10 NEGATIVE , Cyclin D1 NEGATIVE , FMC-7 NEGATIVE (or dim) , and CD103 NEGATIVE . FLOW CYTOMETRY GATING IN CLL

  • CD5 (T-cell Marker) ──► ▲
  • │ ┌───────────────────────────┐
  • │ │ CLASSIC CLL PHENOTYPE │
  • │ │ • CD19+ / CD5+ / CD23+ │
  • │ │ • CD200+ (Bright) │
  • │ │ • CD20 (Dim) / sIg (Dim) │
  • │ │ • CD10- / Cyclin D1- │
  • │ └───────────────────────────┘
  • │
  • └─────────────────────────────────────►
  • CD19 (B-cell Marker)
  • Clinical Staging Systems (Rai and Binet)

Staging System Stage Clinical Features Risk Category Median Survival

Rai System Stage 0 Absolute lymphocytosis only ( > 5.0 × 10 9 / L >5.0 \times 10^9/\text{L} > 5.0 × 1 0 9 / L in blood, ≥ 30 % \ge 30\% ≥ 30% in marrow) Low Risk > 150 >150 > 150 months

  • Stage I Lymphocytosis + Lymphadenopathy Intermediate Risk ~100 months
  • Stage II Lymphocytosis + Splenomegaly and/or Hepatomegaly (± lymphadenopathy) Intermediate Risk ~70 months

Stage III Lymphocytosis + Anemia ( Hb < 11.0 g/dL \text{Hb} < 11.0\text{ g/dL} Hb < 11.0 g/dL ) (± organomegaly) High Risk ~19 months

Stage IV Lymphocytosis + Thrombocytopenia ( Platelets < 100 × 10 9 / L \text{Platelets} < 100 \times 10^9/\text{L} Platelets < 100 × 1 0 9 / L ) High Risk ~19 months

Binet System Stage A < 3 <3 < 3 involved lymphoid areas; no anemia or thrombocytopenia Low Risk > 120 >120 > 120 months

Stage B ≥ 3 \ge 3 ≥ 3 involved lymphoid areas; no anemia or thrombocytopenia Intermediate Risk ~60 months

Stage C Anemia ( Hb < 10.0 g/dL \text{Hb} < 10.0\text{ g/dL} Hb < 10.0 g/dL ) and/or Thrombocytopenia ( Platelets < 100 × 10 9 / L \text{Platelets} < 100 \times 10^9/\text{L} Platelets < 100 × 1 0 9 / L ) High Risk ~24 months

Cytogenetic & Molecular Prognostic Markers

Favorable Prognosis :

del(13q14) (as a sole abnormality): Deletion of the miR-15a/16-1 cluster; seen in > 50 % >50\% > 50% of patients; associated with indolent disease and longest survival.

Mutated I G H V IGHV I G H V : ≥ 2 % \ge 2\% ≥ 2% somatic hypermutation of the Immunoglobulin Heavy Chain Variable region gene compared to germline sequence, indicating origin from a post-germinal center memory B-cell (associated with durable response and prolonged survival).

Unfavorable / Adverse Prognosis :

del(17p13) / T P 53 TP53 TP 53 Mutation : Deletion of the TP53 locus or somatic mutation of T P 53 TP53 TP 53 ; confers primary resistance to standard alkylating/purine chemoimmunotherapy. Patients require targeted therapies ( BTK inhibitors [Ibrutinib, Acalabrutinib, Zanubrutinib] or BCL2 inhibitors [Venetoclax]).

del(11q22-23) / A T M ATM A TM Mutation : Deletion involving the Ataxia Telangiectasia Mutated gene; associated with extensive lymphadenopathy and aggressive progression.

Trisomy 12 ( + 12 +12 + 12 ) : Intermediate-to-adverse risk; associated with atypical morphology and higher CD20 expression.

Unmutated I G H V IGHV I G H V : < 2 % <2\% < 2% somatic hypermutation (germline configuration), indicating a pre-germinal center naive B-cell origin; aggressive clinical course.

Flow Cytometric Surrogates : High expression of CD38 ( ≥ 30 % \ge 30\% ≥ 30% ) and ZAP-70 ( ≥ 20 % \ge 20\% ≥ 20% ) correlates closely with unmutated I G H V IGHV I G H V and poor prognosis.

Major Complications of CLL

Autoimmune Cytopenias : 5–10% of CLL patients develop secondary autoimmune complications mediated by polyclonal IgG autoantibodies produced by non-neoplastic B-cells stimulated by dysregulated T-helper networks: Warm Autoimmune Hemolytic Anemia (WAIHA, DAT/Coombs positive) and Immune Thrombocytopenia (ITP) .

Hypogammaglobulinemia : Progressive reduction in normal polyclonal immunoglobulin synthesis (IgG, IgA, IgM) occurs in > 85 % >85\% > 85% of advanced patients, leading to severe, recurrent bacterial infections (especially encapsulated organisms like S. pneumoniae and H. influenzae ), which represent the leading cause of death.

Richter Transformation (Richter's Syndrome) : Sudden transformation (in 5–10% of patients) of indolent CLL into an aggressive, high-grade Diffuse Large B-Cell Lymphoma (DLBCL) or rarely Hodgkin lymphoma. Manifests clinically as rapid asymmetrical lymph node enlargement, worsening B-symptoms (fever, drenching sweats, weight loss), markedly elevated serum LDH, and a median survival < 6 – 12 <6\text{--}12 < 6 – 12 months.

2. Hairy Cell Leukemia (HCL)

Hairy Cell Leukemia is an uncommon, indolent mature B-cell neoplasm accounting for ~2% of all lymphoid leukemias. It predominantly affects middle-aged to elderly males (median age 55; male-to-female ratio 4:1 to 5:1). HAIRY CELL LEUKEMIA PATHOLOGY

  • │
  • ┌─────────────────────────────┼─────────────────────────────┐
  • ▼ ▼ ▼
  • [ CLINICAL TRIAD ] [ MORPHOLOGY & MARROW ] [ IMMUNOPHENOTYPE & GENETICS ]
  • Massive Splenomegaly • Circumferential "Hair-like" • CD19+, CD20+ (Bright)
  • Pancytopenia with Cytoplasmic Projections • CD11c+, CD25+, CD103+, CD123+
  • Severe Monocytopenia • Spongy, Oval Chromatin • Annexin A1+ (Pathognomonic)
  • Absence of Peripheral • Bone Marrow Reticulin • TRAP Positive
  • Lymphadenopathy Fibrosis ("Dry Tap") • BRAF V600E Mutation (>95%)
  • Clinical Presentation & Smear Morphology

Clinical Hallmarks : Massive splenomegaly (extending into the pelvis) in the absence of peripheral lymphadenopathy , accompanied by pancytopenia with profound monocytopenia (absolute monocyte count often < 0.05 × 10 9 / L <0.05 \times 10^9/\text{L} < 0.05 × 1 0 9 / L , predisposing to opportunistic atypical mycobacterial infections).

Cytology : Leukemic cells are medium-to-large ( 15 – 20 μ m 15\text{--}20\ \mu\text{m} 15 – 20 μ m ) mononuclear cells with abundant pale, grey-blue cytoplasm featuring fine, delicate, circumferential hair-like or serrated cytoplasmic projections . Nuclei are oval, reniform (kidney-shaped), or indented with a distinctive "spongy" or ground-glass chromatin and inconspicuous nucleoli.

Bone Marrow Findings : Aspiration yields a "dry tap" due to diffuse marrow reticulin fibrosis produced by hairy cells. Core biopsy displays a characteristic "fried-egg" appearance —cells are widely separated by clear cytoplasmic halos around uniform round/oval nuclei with distinct cell borders.

Cytochemistry, Genetics & Immunophenotype

Tartrate-Resistant Acid Phosphatase (TRAP) Positive : Incubation of smear preparations with L − ( + ) L-(+) L − ( + ) -tartaric acid inhibits standard lysosomal acid phosphatase isoenzymes 0, 1, 2, 3, and 4, but fails to inhibit isoenzyme 5 (tartrate-resistant) present abundantly in hairy cells, yielding intense red granular cytoplasmic staining.

B R A F BRAF BR A F V600E Somatic Mutation : Present in > 95 – 100 % >95\text{--}100\% > 95 – 100% of classical HCL cases. A point mutation (T1799A) in exon 15 of the BRAF proto-oncogene results in a valine-to-glutamic acid substitution at residue 600, causing constitutive phosphorylation and activation of the MEK-ERK MAPK pathway.

Diagnostic Immunophenotype : Strong expression of pan-B-cell markers ( CD19+, CD20+ bright, sIg+ bright ) co-expressed with the pathognomonic tetrad: CD11c+ (bright) , CD25+ (bright) , CD103+ (bright) , and CD123+ , along with Annexin A1+ (the most specific marker distinguishing classical HCL from variant HCL). CD5, CD10, and CD23 are typically negative.

Therapy : Highly sensitive to purine nucleoside analogues ( Cladribine / 2-CdA or Pentostatin ), achieving durable complete remissions in > 85 % >85\% > 85% of patients; BRAF inhibitors (Vemurafenib) for refractory disease.

  • 3. Other Key Indolent B-Cell Lymphomas
  • A. Follicular Lymphoma (FL)

Pathophysiology : Originates from germinal center B-cells (centrocytes and centroblasts). Characterized cytogenetically by the reciprocal translocation t ( 14 ; 18 ) ( q 32 ; q 21 ) \text{t}(14;18)(\text{q}32;\text{q}21) t ( 14 ; 18 ) ( q 32 ; q 21 ) , which translocates the B C L 2 BCL2 BC L 2 proto-oncogene on chromosome 18q21 to the I G H IGH I G H locus on 14q32. This causes constitutive overexpression of the BCL2 anti-apoptotic protein, suppressing normal programmed cell death in the germinal center.

Morphology : Displays a mixture of centrocytes (small-to-medium cleaved cells with irregular, notched, indented "buttock" nuclei ) and centroblasts (large non-cleaved cells with vesicular chromatin and multiple peripheral nucleoli).

Immunophenotype : CD19+ , CD20+ (bright) , CD10+ , BCL6+ , BCL2+ , surface Ig+ (bright); CD5 NEGATIVE , CD23 negative/variable , and CD43 NEGATIVE .

B. Mantle Cell Lymphoma (MCL)

Pathophysiology : Originates from pre-germinal center naive B-cells in the mantle zone. Defined by the translocation t ( 11 ; 14 ) ( q 13 ; q 32 ) \text{t}(11;14)(\text{q}13;\text{q}32) t ( 11 ; 14 ) ( q 13 ; q 32 ) , which juxtaposes the C C N D 1 CCND1 CCN D 1 ( B C L 1 BCL1 BC L 1 ) gene on 11q13 to the I G H IGH I G H enhancer on 14q32. This drives continuous nuclear overexpression of Cyclin D1 , forcing cells through the G1/S cell cycle checkpoint.

Morphology : Monomorphic population of small-to-medium lymphocytes with irregular, indented nuclear contours and condensed chromatin.

Immunophenotype & Critical Differentiation from CLL : CD19+ , CD20+ (bright) , CD5+ , CD43+ , and Cyclin D1+ (nuclear) , along with SOX11+ . Unlike CLL, Mantle Cell Lymphoma is CD23 NEGATIVE , CD200 NEGATIVE , and expresses bright surface immunoglobulin.

C. Marginal Zone Lymphoma (MZL) / MALT Lymphoma

Pathophysiology : Originates from memory B-cells in the marginal zone of lymphoid follicles. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue ( MALT lymphoma ) arises in tissues chronically inflamed by autoimmune disease or infection: H e l i c o b a c t e r p y l o r i Helicobacter\ pylori He l i co ba c t er p y l or i gastritis, Hashimoto thyroiditis , and Sjögren syndrome (salivary glands).

Immunophenotype : CD19+ , CD20+ , CD79a+ , CD43+ ; CD5 NEGATIVE , CD10 NEGATIVE , CD23 NEGATIVE , and Cyclin D1 NEGATIVE .

4. Flow Cytometry & Cytogenetic Differential Matrix of Mature B-Cell Disorders

Neoplasm Key Morphology CD5 CD10 CD23 CD200 Cyclin D1 Other Specific Markers Hallmark Cytogenetics / Mutation

CLL / SLL Soccer-ball chromatin, smudge cells Positive Negative Positive Bright + Negative CD20 dim, sIg dim, CD43+ del(13q), del(17p), del(11q), I G H V IGHV I G H V mutation

Mantle Cell (MCL) Cleaved, indented small/medium cells Positive Negative Negative Negative Positive SOX11+, CD20 bright, sIg bright t ( 11 ; 14 ) \text{t}(11;14) t ( 11 ; 14 ) C C N D 1 : : I G H CCND1::IGH CCN D 1 :: I G H

Follicular (FL) Centrocytes (buttock cells), centroblasts Negative Positive Negative Negative Negative BCL6+, BCL2+, CD20 bright t ( 14 ; 18 ) \text{t}(14;18) t ( 14 ; 18 ) B C L 2 : : I G H BCL2::IGH BC L 2 :: I G H

Hairy Cell (HCL) Circumferential hair-like projections Negative Negative Negative Negative Negative CD11c+, CD25+, CD103+, Annexin A1+ B R A F BRAF BR A F V600E (TRAP+)

Marginal Zone (MZL) Monocytoid B-cells, plasmacytoid Negative Negative Negative Variable Negative CD43+, CD20 bright t ( 11 ; 18 ) \text{t}(11;18) t ( 11 ; 18 ) in MALT; H . p y l o r i H.\ pylori H . p y l or i assoc.

Loading diagram... Immunophenotypic Flow Cytometry Decision Tree for Mature B-Cell Neoplasms